Distribution of the subjects within groups, characteristics and vascular density
Control group | Group 1—mild disease | Group 2—moderate disease | Group 3—severe disease | Significance among all groups | ||
Gender | Male | 10 | 12 | 10 | 12 | 0.520* |
Female | 17 | 12 | 14 | 9 | ||
Age (years) | Mean | 39 | 41 | 42 | 44 | 0.333† |
Diabetes | No | 27 | 24 | 22 | 19 | 0.189* |
Yes | 0 | 0 | 2 | 2 | ||
Smoker | No | 22 | 21 | 24 | 19 | 0.186* |
Yes | 5 | 3 | 0 | 2 | ||
Race | Caucasic | 27 | 23 | 19 | 11 | 0.001*§ |
Latin | 0 | 1 | 5 | 9 | ||
Other | 0 | 0 | 0 | 1 | ||
ACEI use | No | 26 | 24 | 24 | 20 | 0.550* |
Yes | 1 | 0 | 0 | 1 | ||
Days from PCR | Mean | – | – | 72 | 70 | – |
Central VD | Mean | 16.90 | 17.16 | 13.37 | 13.63 | 0.000†§ |
SD | 3.10 | 3.48 | 4.90 | 3.78 | ||
Inferior VD | Mean | 50.37 | 49.55 | 49.67 | 48.78 | 0.827‡ |
SD | 3.25 | 2.63 | 4.88 | 4.56 | ||
Superior VD | Mean | 49.72 | 48.82 | 49.03 | 49.46 | 0.733† |
SD | 3.43 | 2.99 | 2.70 | 3.28 | ||
Nasal VD | Mean | 43.92 | 44.26 | 43.86 | 44.21 | 0.970† |
SD | 2.59 | 4.41 | 2.80 | 7.74 | ||
Temporal VD | Mean | 47.77 | 45.99 | 48.41 | 47.87 | 0.020‡§ |
SD | 2.20 | 3.46 | 4.19 | 3.97 | ||
FAZ | Mean | 0.25 | 0.20 | 0.35 | 0.31 | 0.000‡ |
SD | 0.07 | 0.08 | 0.15 | 0.10 | ||
Image quality | Mean | 64,96 | 64.13 | 66,88 | 65,95 | 0.441‡ |
SD | 5,21 | 6,61 | 4,25 | 4,75 |
*Χ2 test.
†ANOVA test and Bonferroni correction.
‡Kruskal-Wallis and Mann-Whitney U test.
§Statistically significant p<0.05.
ACEI, ACE inhibitor; ANOVA, analysis of variance; FAZ, foveal avascular zone; VD, vascular density.